Conclusions : Isoflavone treatments exert a moderately beneficial effect against  estrogen-deficient bone loss in women .
The effect appears dependent on whether isoflavone treatments are in aglycone form ; we conclude that beneficial effects against bone loss may be enhanced for isoflavone aglycones
Background : Age-related estrogen deficiency leads to accelerated bone resorption .
There is evidence that , through selective estrogen receptor modulation , isoflavones may exert beneficial effects against  estrogen-deficient bone loss .
Isoflavone aglycones show higher bioavailability than their glycosidic counterparts and thus may have greater potency .
Objective : To summarize evidence , we executed a systematic review and meta- analysis examining isoflavone therapies and bone mineral density ( BMD ) loss in peri- and postmenopausal women .
Effect of a combination of genistein, polyunsaturated fatty acids and vitamins D3 and K1 on bone mineral density in postmenopausal women: a randomized, placebo-controlled, double-blind pilot study
Purpose Many postmenopausal women desire non-pharmaceutical alternatives to hormone therapy for protection against osteoporosis . Soybean isoflavones , especially genistein , are being studied for this purpose . This study examined the effects of synthetic genistein in combination with other potential bone-protective dietary molecules on bone mineral density ( BMD ) in early postmenopausal women . Methods In this 6-month double-blind pilot study , 70 subjects were r and omized to receive daily either calcium only or the geniVida ™ bone blend ( GBB ) , which consisted of genistein ( 30 mg/days ) , vitamin D3 ( 800 IU/days ) , vitamin K1 ( 150 μg/days ) and polyunsaturated fatty acids ( 1 g polyunsaturated fatty acids as ethyl ester : eicosapentaenoic acid/docosahexaenoic acid ratio = ~2/1 ) . Markers of bone resorption and formation and BMD at the femoral neck , lumbar spine , Ward ’s triangle , trochanter and intertrochanter , total hip and whole body were assessed . Results Subjects supplemented with the GBB ( n = 30 ) maintained femoral neck BMD , whereas in the placebo group ( n = 28 ) , BMD significantly decreased ( p = 0.007 ) . There was also a significant difference ( p < 0.05 ) in BMD between the groups at Ward ’s triangle in favor of the GBB group . Bone-specific alkaline phosphatase and N-telopeptide significantly increased in the GBB group in comparison with those in baseline and in the placebo group . The GBB was well tolerated , and there were no significant differences in adverse events between groups . Conclusions The GBB may help to prevent osteoporosis and reduce fracture risk , at least at the hip , in postmenopausal women . Larger and longer-term clinical trials are warranted
Conclusions : Isoflavone treatments exert a moderately beneficial effect against  estrogen-deficient bone loss in women .
The effect appears dependent on whether isoflavone treatments are in aglycone form ; we conclude that beneficial effects against bone loss may be enhanced for isoflavone aglycones
Background : Age-related estrogen deficiency leads to accelerated bone resorption .
There is evidence that , through selective estrogen receptor modulation , isoflavones may exert beneficial effects against  estrogen-deficient bone loss .
Isoflavone aglycones show higher bioavailability than their glycosidic counterparts and thus may have greater potency .
Objective : To summarize evidence , we executed a systematic review and meta- analysis examining isoflavone therapies and bone mineral density ( BMD ) loss in peri- and postmenopausal women .